Savara Announces Participation in the Leerink Global Healthcare Conference
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company specializing in rare respiratory diseases, has announced its upcoming participation in the Leerink Global Healthcare Conference. The company's management team will engage in a fireside chat scheduled for Tuesday, March 11th at 10:40am ET/7:40am PT.
The event will be accessible through a live webcast and will remain available for replay on Savara's corporate website under the 'Events & Presentations' section for 90 days following the presentation.
Savara Inc. (Nasdaq: SVRA), un'azienda biofarmaceutica in fase clinica specializzata in malattie respiratorie rare, ha annunciato la sua prossima partecipazione alla Leerink Global Healthcare Conference. Il team di gestione dell'azienda parteciperà a una chiacchierata informale programmata per martedì 11 marzo alle 10:40 ET/7:40 PT.
L'evento sarà accessibile tramite una diretta web e rimarrà disponibile per la riproduzione sul sito web aziendale di Savara nella sezione 'Eventi e Presentazioni' per 90 giorni dopo la presentazione.
Savara Inc. (Nasdaq: SVRA), una compañía biofarmacéutica en etapa clínica especializada en enfermedades respiratorias raras, ha anunciado su próxima participación en la Leerink Global Healthcare Conference. El equipo de gestión de la compañía participará en una charla informal programada para el martes 11 de marzo a las 10:40 a.m. ET/7:40 a.m. PT.
El evento será accesible a través de una transmisión en vivo y estará disponible para su reproducción en el sitio web corporativo de Savara en la sección 'Eventos y Presentaciones' durante 90 días después de la presentación.
사바라 주식회사 (Nasdaq: SVRA)는 희귀 호흡기 질환을 전문으로 하는 임상 단계의 생명공학 회사로, 리어링크 글로벌 헬스케어 컨퍼런스에 참여할 예정이라고 발표했습니다. 회사의 경영진은 3월 11일 화요일 오전 10:40 ET/오전 7:40 PT로 예정된 화상 대화에 참여할 것입니다.
이번 이벤트는 라이브 웹캐스트를 통해 접근할 수 있으며, 발표 후 90일 동안 사바라의 기업 웹사이트 '이벤트 및 프레젠테이션' 섹션에서 다시 볼 수 있습니다.
Savara Inc. (Nasdaq: SVRA), une entreprise biopharmaceutique en phase clinique spécialisée dans les maladies respiratoires rares, a annoncé sa prochaine participation à la Leerink Global Healthcare Conference. L'équipe de direction de l'entreprise participera à une discussion informelle prévue pour le mardi 11 mars à 10h40 ET/7h40 PT.
L'événement sera accessible via un webinaire en direct et restera disponible en replay sur le site web de Savara dans la section 'Événements et Présentations' pendant 90 jours après la présentation.
Savara Inc. (Nasdaq: SVRA), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf seltene Atemwegserkrankungen spezialisiert hat, hat seine bevorstehende Teilnahme an der Leerink Global Healthcare Conference angekündigt. Das Management-Team des Unternehmens wird an einem informellen Gespräch teilnehmen, das für Dienstag, den 11. März, um 10:40 Uhr ET/7:40 Uhr PT geplant ist.
Die Veranstaltung wird über einen Live-Stream zugänglich sein und bleibt für 90 Tage nach der Präsentation auf der Unternehmenswebsite von Savara im Bereich 'Veranstaltungen & Präsentationen' verfügbar.
- None.
- None.
The live webcast and subsequent replay will be available on the “Events & Presentations” section of the Company’s corporate website at https://savarapharma.com/investors/events-presentations/ and will be archived for 90 days.
Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, MOLBREEVI*, is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). MOLBREEVI is delivered via an investigational eFlow® Nebulizer System (PARI Pharma GmbH) specifically developed for inhalation of a large molecule. Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at www.savarapharma.com, and LinkedIn.
*MOLBREEVI is the FDA and EMA conditionally accepted trade name for molgramostim inhalation solution. It is not approved in any indication.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250303602288/en/
Media and Investor Relations Contact
Savara Inc.
Temre Johnson, Executive Director, Corporate Affairs
ir@savarapharma.com
Source: Savara Inc.
FAQ
When is Savara (SVRA) presenting at the Leerink Global Healthcare Conference?
How can investors watch Savara's (SVRA) Leerink Conference presentation?
How long will Savara's (SVRA) Leerink Conference presentation be available for replay?
What is Savara's (SVRA) main business focus?
